Table 3.
Ascitic culture and antibiotic resistance in SBP.
| No. of papers | Sample (SBP) | Events (positive) | Pooled prevalence (95% CI) | |
|---|---|---|---|---|
| Ascites culture | ||||
| Culture positive | 39 | 4,608 | 1,844 | 39.50% (31.85–47.71%) |
| CNNA | 31 | 3,827 | 2,149 | 55.85% (43.25–67.74%) |
| BA | 12 | 1,542 | 604 | 23.96% (13.74–38.39%) |
| Antibiotic resistant | 32 | 3,263 | 317 | 11.77% (7.63–17.73%) |
| North America | 3 | 329 | 54 | 17.83% (2.83–61.73%) |
| Asia Pacific | 3 | 524 | 60 | 11.0% (4.65–23.85%) |
| Middle East | 1 | 200 | 12 | 6.0% (3.44–10.27%) |
| Latin America | 2 | 189 | 11 | 5.82% (3.25–10.20%) |
| Europe | 11 | 1,300 | 180 | 12.3% (7.07–20.53%) |
| ESBL | ||||
| Total | 12 | 1,720 | 129 | 6.19% (3.32–11.26%) |
| North America | 3 | 329 | 35 | 10.18% (2.34–34.90%) |
| Asia Pacific | 3 | 524 | 58 | 9.88% (4.69–19.65%) |
| Middle East | 1 | 200 | 12 | 6.0% (3.44–10.27%) |
| Europe | 5 | 667 | 24 | 3.35% (1.39–7.84%) |
| MRSA | ||||
| Total | 10 | 951 | 63 | 6.23%% (3.83–9.97%) |
| Europe | 8 | 770 | 54 | 6.63% (3.70–11.61%) |
| Latin America | 1 | 134 | 7 | 5.22% (2.51–10.55%) |
| North America | 1 | 47 | 2 | 4.26% (1.07–15.48%) |
| VRE | ||||
| Total | 3 | 258 | 4 | 1.91% (0.41–8.46%) |
| North America | 2 | 239 | 2 | 0.84% (0.21–3.28%) |
| Europe | 1 | 19 | 2 | 10.53% (2.65–33.74%) |
CNNA, culture negative neutrocytic ascites; BA, bacterascites; ESBL, extended spectrum beta-lactamase; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococcus.